BRPI0607349A2 - combinação de xolair com agente imunossupressor - Google Patents

combinação de xolair com agente imunossupressor

Info

Publication number
BRPI0607349A2
BRPI0607349A2 BRPI0607349-2A BRPI0607349A BRPI0607349A2 BR PI0607349 A2 BRPI0607349 A2 BR PI0607349A2 BR PI0607349 A BRPI0607349 A BR PI0607349A BR PI0607349 A2 BRPI0607349 A2 BR PI0607349A2
Authority
BR
Brazil
Prior art keywords
xolair
combination
immunosuppressive agent
pharmaceutically acceptable
agent
Prior art date
Application number
BRPI0607349-2A
Other languages
English (en)
Inventor
Charles Edward Owen
Howard George Fox
Christoph Walker
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0607349A2 publication Critical patent/BRPI0607349A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMBINAçãO DE XOLAIR COM AGENTE IMUNOSSUPRESSOR. A presente invenção refere-se a uma composição farmacêutica compreendendo um anticorpo anti-IgE e pelo menos um outro agente imunossupressor, na qual os ingredientes ativos estão, em cada caso, na forma livre ou na forma de um sal farmaceuticamente aceitável e opcionalmente pelo menos um carreador farmaceuticamente aceitável; para uso simultâneo, separado ou seqúencial.
BRPI0607349-2A 2005-02-04 2006-02-02 combinação de xolair com agente imunossupressor BRPI0607349A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0502358.5A GB0502358D0 (en) 2005-02-04 2005-02-04 Organic compounds
PCT/EP2006/000911 WO2006082052A1 (en) 2005-02-04 2006-02-02 Synergistic combination of xolair/omalizumab/e25 with immunosuppressive agent

Publications (1)

Publication Number Publication Date
BRPI0607349A2 true BRPI0607349A2 (pt) 2009-09-01

Family

ID=34355808

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607349-2A BRPI0607349A2 (pt) 2005-02-04 2006-02-02 combinação de xolair com agente imunossupressor

Country Status (20)

Country Link
US (1) US20080206237A1 (pt)
EP (1) EP1846031A1 (pt)
JP (1) JP2008528650A (pt)
KR (1) KR20070100344A (pt)
CN (1) CN101111265A (pt)
AR (1) AR053541A1 (pt)
AU (1) AU2006210098A1 (pt)
BR (1) BRPI0607349A2 (pt)
CA (1) CA2595976A1 (pt)
GB (1) GB0502358D0 (pt)
GT (1) GT200600023A (pt)
IL (1) IL184713A0 (pt)
MA (1) MA29273B1 (pt)
MX (1) MX2007009436A (pt)
NO (1) NO20074497L (pt)
PE (1) PE20061203A1 (pt)
RU (1) RU2007132980A (pt)
TN (1) TNSN07304A1 (pt)
TW (1) TW200640487A (pt)
WO (1) WO2006082052A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2595960A1 (en) * 2005-02-08 2006-08-17 Novartis Ag Antilymphocyte antibody induction by combination of an s1p receptor agonist/modulator and of immunosuppressive drugs
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
BRPI0918670B8 (pt) * 2008-09-17 2021-05-25 Xencor Inc anticorpo
CA2784498A1 (en) * 2009-12-18 2011-06-23 Sanofi Novel antagonist antibodies and their fab fragments against gpvi and uses thereof
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
AR085749A1 (es) * 2011-04-01 2013-10-23 Novartis Ag Formulaciones
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
CA2972393A1 (en) 2015-02-27 2016-09-01 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
US10947320B2 (en) 2015-12-18 2021-03-16 University Of Notre Dame Du Lac Covalent heterobivalent antibody inhibitors and ligands
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
WO2018139623A1 (en) 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
DE102017215154A1 (de) 2017-08-30 2019-02-28 Markus Bläss Zusammensetzung zur topischen Behandlung von nicht-Mikroorganismus-verursachten entzündlichen Haut- und Schleimhauterkrankungen
US12030959B1 (en) 2023-07-05 2024-07-09 Genentech, Inc. Anti-IgE antibody therapy for multiple food allergies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6172213B1 (en) * 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
GB0200429D0 (en) * 2002-01-09 2002-02-27 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
AR053541A1 (es) 2007-05-09
GT200600023A (es) 2006-08-16
CA2595976A1 (en) 2006-08-10
MA29273B1 (fr) 2008-02-01
PE20061203A1 (es) 2006-12-19
JP2008528650A (ja) 2008-07-31
IL184713A0 (en) 2007-12-03
AU2006210098A1 (en) 2006-08-10
TNSN07304A1 (en) 2008-12-31
RU2007132980A (ru) 2009-03-10
CN101111265A (zh) 2008-01-23
WO2006082052A1 (en) 2006-08-10
NO20074497L (no) 2007-10-26
EP1846031A1 (en) 2007-10-24
GB0502358D0 (en) 2005-03-16
KR20070100344A (ko) 2007-10-10
MX2007009436A (es) 2007-08-17
US20080206237A1 (en) 2008-08-28
TW200640487A (en) 2006-12-01

Similar Documents

Publication Publication Date Title
BRPI0607349A2 (pt) combinação de xolair com agente imunossupressor
BRPI0718523B8 (pt) Forma de dosagem, e, método para preparar a forma de dosagem
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
JP2012509886A5 (pt)
WO2007147001A3 (en) Lyophilized formulations of anti-egfr antibodies
BRPI0513841A (pt) composto, composição farmacêutica, e uso do composto
WO2004089396A3 (en) Anti-fungal peptidomimetics
BR122012030846B8 (pt) composição farmacêutica não aquosa para uso dermatológico compreendendo calcipotriol e pelo menos um corticoesteróide, e, uso da mesma
BRPI0514474A (pt) multiparticulados
AR071852A1 (es) Formulacion farmaceutica de un anticuerpo frente a ox40l
AR054511A1 (es) Una composicion que comprende emtricitabina y tenofovir df granuladas en seco
AR080795A1 (es) Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6)
BRPI0416752B8 (pt) composição farmacêutica, uso de um ou mais compostos, e, compostos
AR073717A1 (es) Anticuerpos anti-notch2 de murino y humano, y metodos de uso
BRPI0709847B8 (pt) composição farmacêutica sólida de liberação rápida contendo paracetamol e carbonato de cálcio
BRPI0615860B8 (pt) composição farmacêutica de liberação prolongada monolítica sólida
EA200970469A1 (ru) Антитела-агонисты рецептора trkb и их применение
BR112013015786A2 (pt) composição de agente de formação de imagem, método de formação de imagem de pelo menos uma parte de um indivíduo, e, método para preparar uma composição de polipeptídeo conjugado com quelante
CL2004000930A1 (es) Compuesto derivado de dihidroquinazolina de formula definida, util para el tratamiento y/o profilaxis de infecciones virales; composicion farmaceutica que comprende al compuesto y uso del compuesto en la preparacion de medicamentos.
CR8428A (es) Agente endoparasiticidas para la administracion topica
ATE556717T1 (de) Neutralisierung monoklonaler antikörper gegen mit schwerem akutem respirationssyndrom assoziiertem coronavirus
EP2000541A4 (en) HUMANIZED MONOCLONAL ANTI-CD20 ANTIBODY
CL2007002619A1 (es) Compuestos derivados de 3-aza-biciclo[4.1.0]heptano; composicion farmaceutica; y uso en el tratamiento de la depresion.
IL179240A (en) Use of an antibody bound to the complement component 5c for the preparation of drugs to assess the survival of an implant, and pharmaceutical packaging and injection kits containing this antibody
BR0306732A (pt) Tratamentos em combinação para doença alérgica compreendendo a administração de um anticorpo anti-ige e composto antialérgico

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]